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Abstract
Introduction Annually, millions of adults suffer hip
fractures. The mortality rate post a hip fracture is 7%–
10% at 30 days and 10%–20% at 90 days. Observational
data suggest that early surgery can improve these
outcomes in hip fracture patients. We designed a clinical
trial—HIP fracture Accelerated surgical TreaTment
And Care tracK (HIP ATTACK) to determine the effect of
accelerated surgery compared with standard care on the
90-day risk of all-cause mortality and major perioperative
complications.
Methods and analysis HIP ATTACK is a multicentre,
international, parallel group randomised controlled
trial (RCT) that will include patients ≥45 years of age
and diagnosed with a hip fracture from a low-energy
mechanism requiring surgery. Patients are randomised to
accelerated medical assessment and surgical repair (goal
within 6 h) or standard care. The co-primary outcomes
are (1) all-cause mortality and (2) a composite of major
perioperative complications (ie, mortality and non-fatal
myocardial infarction, pulmonary embolism, pneumonia,
sepsis, stroke, and life-threatening and major bleeding) at
90 days after randomisation. All patients will be followed
up for a period of 1 year. We will enrol 3000 patients.
Ethics and dissemination All centres had ethics approval
before randomising patients. Written informed consent is
required for all patients before randomisation. HIP ATTACK
is the first large international trial designed to examine
whether accelerated surgery can improve outcomes
in patients with a hip fracture. The dissemination plan
includes publishing the results in a policy-influencing

Strengths and limitations of this study
►► HIP fracture Accelerated surgical TreaTment And

Care tracK (HIP ATTACK) is the first large randomised
controlled trial powered to determine the effects of
accelerated surgery compared with the standard of
care in hip fracture patients.
►► HIP ATTACK trial implemented patient engagement
strategies, including research governance, trial outcome evaluation and knowledge translation.
►► Patients, healthcare providers and study personnel
are unblinded to patient treatment allocation; however, outcome adjudicators are blinded to treatment
allocation.
►► HIP ATTACK will only inform the effect of accelerated
surgery versus standard care during hospital working hours and does not inform the effects outside of
working hours.

journal, conference presentations, engagement of
influential medical organisations, and providing public
awareness through multimedia resources.
Trial registration number NCT02027896; Pre-results.

Introduction
Worldwide, millions of adults suffer a hip
fracture annualy.1 A hip fracture results in
trauma, pain, bleeding and immobility. These
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factors may trigger inflammation, hypercoagulability,
catabolism and stress,2–5 which can precipitate perioperative complications. The most commonly reported causes
of short-term mortality after a hip fracture are coronary
heart disease, stroke, pneumonia, sepsis and pulmonary
embolism.6 7 The mortality rate post a hip fracture is 7%
to 10% at 30 days and 10% to 20% at 90 days.8–13
The impact of early surgery on the risk of perioperative complications and mortality in hip fracture patients
was evaluated in a systematic review and meta-analysis of
observational studies.14 Earlier surgery was associated with
a significant reduction in mortality (relative risk [RR],
0.81; 95% CI 0.68 to 0.96; p=0.01) in five studies (4208
patients,721 deaths). Earlier surgery was also associated
with reduced risk of pressure sores (RR, 0.48; 95% CI 0.34
to 0.69; p<0.001) and in-hospital pneumonia (RR, 0.59;
95% CI 0.37 to 0.93; p=0.02).14
The HIP fracture Accelerated surgical TreaTment And
Care tracK (HIP ATTACK) Pilot Trial included 60 patients
and established the feasibility of a trial of accelerated
surgery in patients with a hip fracture. Among patients
randomised to accelerated surgery, 30% had a major
perioperative complication (ie, mortality and non-fatal
preoperative myocardial infarction [MI], myocardial
injury after noncardiac surgery, pulmonary embolism,
pneumonia, stroke, and life-threatening and major
bleeding) within 30 days of randomisation as compared
with 47% of the patients allocated to standard care (HR ,
0.60; 95% CI 0.26 to 1.39; p=0.23).15
We designed the HIP ATTACK Trial to determine the
effect of accelerated medical clearance and accelerated
surgery compared with standard care on the 90-day
risk of the following two co-primary outcomes: all-cause
mortality and major perioperative complications.

Methods and analysis
Trial design
The HIP ATTACK Trial is a multicentre international,
parallel group randomised controlled trial (RCT) of 3000
patients with a hip fracture that requires a surgical intervention. Patients are randomised to accelerated medical
assessment and surgical repair (ie, goal of surgery within
6 hours of hip fracture diagnosis) or standard care.
Trial population
We include patients ≥45 years of age who were diagnosed
with a hip fracture during working hours, due to a low-energy mechanism, and requiring surgery. All centres are
able to define their own study working hours according to
the feasibility of randomising patients to the accelerated
surgery within 6 hours from diagnosis. Box 1 reports the
exclusion criteria.
Currently, across Canada, 80%–90% of patients with
a hip fracture undergo hip surgery within 48 hours after
the diagnosis.16 To minimise the variation in the timing of
surgery between centres, we have only included centres
2

Box 1

Exclusion criteria of the HIP ATTACK trial

Patients fulfilling any of the following criteria are excluded:
►► Requiring emergent surgery or emergent interventions for anoth-

er reason (eg, subdural hematoma, abdominal pathology requiring
urgent laparotomy, acute limb ischemia, other fractures or trauma
requiring emergent surgery, necrotising fasciitis, coronary revascularisation, pacemaker-implantation).
►► Open hip fracture.
►► Bilateral hip fractures.
►► Peri-prosthetic fracture.
►► Therapeutic anticoagulation not induced by a vitamin K antagonist,
unfractionated heparin (eg, any administration of therapeutic low
molecular weight heparin [>6000 u/24 hours] in the 24 hours prior
to enrolment) or intake of any other oral anticoagulant(s) for which
there is no reversing agent available.
►► Taking a therapeutic vitamin K antagonist with a history of heparin-induced thrombocytopaenia.
►► Refusing participation.
►► Previously enrolled in the trial.
HIP ATTACK , HIP fracture Accelerated surgical TreaTment And Care tracK.

that have >80% of their hip fracture patients undergoing
surgery within 48 hours.
Patient recruitment
Emergency department physicians and nurses receive
a trial in-service, during which we encourage them to
triage patients with a potential hip fracture for rapid
assessment during working hours, similar to how patients
with a potential MI or stroke are rapidly assessed. The
radiology department expedites imaging of all potential
hip fractures during working hours. Immediately on diagnosing a hip fracture, the emergency department physician consults the orthopaedic team on call and informs
the HIP ATTACK research team about the patient.
After reviewing the films and confirming a hip fracture
requiring surgical intervention, the orthopaedic surgeon
immediately informs the study personnel. Research
personnel approach all eligible patients to participate in
the trial.
Randomisation and blinding
Randomisation occurs immediately after a patient
is deemed eligible and written informed consent is
obtained. Research personnel randomise the patients via
an Interactive Web Randomisation System (IWRS). The
IWRS is a 24 hours computerised randomisation internet
system maintained by the coordinating centre at the
Population Health Research Institute (PHRI), which is
part of Hamilton Health Sciences and McMaster University in Hamilton, Ontario, Canada.
The randomisation process uses block randomisation
stratified by the centre and by the type of planned surgery
(open reduction and internal fixation; or arthroplasty).
We use randomly varying block sizes; the study personnel
and investigators are not aware of the exact sizes. We
randomise patients in a 1:1 fashion to receive accelerated
Borges FK, et al. BMJ Open 2019;9:e028537. doi:10.1136/bmjopen-2018-028537
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Figure 1 The HIP ATTACK RCT flow chart. ECG, electrocardiogram; HIP ATTACK, HIP fracture Accelerated surgical TreaTment
And Care tracK; NPO, nil per os; OR, operating room; RCT, randomised controlled trial.

medical clearance and accelerated surgery versus standard
care (figure 1). The randomisation procedure ensures
concealment for the purpose of minimising bias. Due to
the nature of the trial, it is not possible to blind research
personnel, participants or care providers involved in
a patient’s care. Outcome assessors are blinded to the
trial intervention.
Trial intervention
Patients randomised to accelerated care undergo medical
clearance by a medical specialist (ie, internist, geriatrician, cardiologist or anaesthesiologist), who is available
to quickly arrive in the emergency department for the
assessment. This specialist uses his/her own individual
judgement regarding management when considering
any medical conditions identified, and weighs the potential benefits of delaying surgery for medical management
versus the potential negative consequences of protracted
exposure to the inflammatory, hypercoagulable, stress
and catabolic states associated with a hip fracture. The
medical specialist is aware of all the conditions that the
trial consensus group believe are likely to benefit from
medical optimisation before surgery (box 2).
Following medical clearance, the orthopaedic surgeon
and anaesthesiologist need to agree that the patient is
appropriate for surgery for the case to proceed. Patients
Borges FK, et al. BMJ Open 2019;9:e028537. doi:10.1136/bmjopen-2018-028537

randomised to accelerated care (ie, medical clearance
and surgery), who are therapeutically anticoagulated with
a vitamin K antagonist, receive prothrombin complex
concentrate to target an International Normalised Ratio
(INR) <1.5.
Patients randomised to accelerated care, after obtaining
medical clearance, move into the next orthopaedic
trauma room or elective operating room slot depending
on availability (ie, they are prioritised over scheduled
elective cases). In centres with a dedicated trauma room,
there is minimal impact to the workflow with case priorities being adjusted to accommodate the HIP ATTACK
case booking. In addition, on evenings or weekends, HIP
ATTACK patients are prioritised over other non-urgent
emergency cases. Immediately after medical clearance
is obtained, research personnel inform all the relevant
stakeholders (ie, surgical booking clerk, orthopaedic
surgeon and anaesthesiologist) to facilitate the exchange
of the elective and the accelerated hip fracture case. The
scheduled elective cases shift a slot forward, and therefore they occur a few hours later than originally planned.
Patients randomised to standard care undergo medical
clearance based on local standard practices. After the
patient is medically cleared, he/she is waitlisted for
surgery according to local standard practices.
3
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Box 2 Conditions likely to benefit from medical
optimisation prior to surgery
►► Acute myocardial infarction associated with a mechanical complica-

tion or ST-elevation myocardial infarction.
►► Cardiac arrest.
►► Cardiogenic shock or frank pulmonary oedema.
►► Respiratory failure requiring mechanical ventilation.
►► Known pulmonary artery hypertension (>80 mmHg).
►► Home oxygen therapy with concomitant clopidogrel.
►► Presumptive bacteremia.
►► Hereditary or acquired coagulopathy that cannot be corrected within

2 hours to an INR <1.5.

9

►► Thrombocytopaenia (platelets <75 ×10 /L) of unknown origin that

cannot be corrected within 2 hours or in case of known chronic
thrombocytopaenia with Platelets <50 ×109/L.
►► Deep venous thrombosis in the last month requiring implantation of
vena cava filter.
►► Acute stroke within 7 days of fracture.
►► Subarachnoid haemorrhage within 1 month of fracture.
►► Impaired consciousness of unknown origin (GCS<12).
►► Fractures during seizure without known history of epilepsy.
►► Na<120 mmol/L
or
>155 mmol/L;
or
Na<125 mmol/L
or >150 mmol/L with neurological symptoms.
►► K>5.5 mmol/L with QRS-complex >120 ms in patients without
known previous QRS-complex >120 ms or K<2.8 mmol/L not
amenable to correction within 2 hours.
►► pH<7.15, not amenable to correction within 2 hours.
►► Indication for acute dialysis.
GCS, Glasgow Coma Scale; INR, International normalised ratio.

The central data management team monitors data
quality, adherence to the trial intervention and provides
a feedback to local investigators to ensure adherence to
the protocol.
Co-interventions
For patients undergoing arthroplasty, the choice of
the surgical implant is left to the surgeon’s discretion
in both accelerated and standard care groups. All other
perioperative management (monitoring, fluids, type of
anaesthesia, analgesia and transfusions) and postoperative care are at the discretion of the attending anaesthesiologist, surgeon and medical specialist. Study personnel
record data on co-interventions. Study investigators
strongly encourage appropriate venous thromboembolism prophylaxis in all randomised patients. We also advocate early mobilisation within 12 hours of hip surgery in
all randomised patients, unless medically or surgically
contraindicated.
Follow-up
All trial patients receive the same structured follow-up
assessment. Research personnel follow patients
throughout their time in hospital evaluating them,
reviewing their medical records, ensuring trial orders
are followed and noting any outcomes. The research
personnel contact the patients by telephone at 30 days, 90
days and 1 year after randomisation. If patients indicate
4

that they have experienced an outcome, the study team
obtains the appropriate documentation.
To accurately capture perioperative MI, we obtain daily
troponin measurements until day 7 after randomisation.
Research personnel screen all patients for postoperative delirium applying the confusion assessment method
(CAM)17 18 daily from day 1 to 7 after randomisation.
Study personnel administer the short form quality of life
(SF-36) questionnaire19 to address patients’ quality of life
at baseline, 30 days, and 1 year after randomisation. Functional independence measure (FIM) motor domain is
determined at 30 days and 1 year, as validated in hip fracture patients.20 The phone administration of the SF-36
questionnaire has also been validated in hip arthroplasty
patients.21 Research personnel are trained in administering the CAM, FIM and SF-36. Research personnel
record all the trial data on case report forms with information entered directly into an electronic data capture
programme (iDataFax).
Trial outcomes
There are two primary outcomes: (1) all-cause mortality
at 90 days after randomisation and (2) composite of major
perioperative complications (ie, mortality, and non-fatal
MI, pulmonary embolism, pneumonia, sepsis, stroke,
and life-threatening and major bleeding) at 90 days after
randomisation.
Individual secondary outcomes at 90 days after randomisation include all-cause mortality, vascular mortality,
non-vascular mortality, MI, myocardial injury after randomisation not meeting the third universal definition of
MI),22–24 cardiac revascularisation procedure (ie, percutaneous coronary intervention or coronary artery bypass
grafting surgery), congestive heart failure, new clinically
important atrial fibrillation, non-fatal cardiac arrest,
stroke, peripheral arterial thrombosis, pulmonary embolism, deep venous thrombosis, pneumonia, sepsis, infection, life-threatening bleeding, major bleeding, acute
kidney injury, new acute renal failure resulting in dialysis, peri-prosthetic fracture, prosthetic hip dislocation,
implant failure, hip re-operation, time to first mobilisation, length of hospital stay, length of critical care stay,
length of rehabilitation stay, new residence in a nursing
home, new pressure ulcers and persistent post-surgical
pain. Online supplementary appendix 1 describes all
outcome definitions.
The FIM motor domain and its mobility and locomotion subscores, and the SF-36 score are assessed at 30
days after randomisation.19 25 An additional secondary
outcome is delirium up to 7 days after randomisation. We
determine the presence of delirium using CAM, which is
a validated tool for the detection of delirium in elderly
hospitalised patients.17 18 For the diagnosis of delirium,
the CAM requires acute fluctuating changes in mental
status, including inattention, incoherent thoughts and
alterations in the consciousness level.17
The motor domain of FIM consists of 13 items each
scored 1 to 7.26 The motor domain scores range from 13
Borges FK, et al. BMJ Open 2019;9:e028537. doi:10.1136/bmjopen-2018-028537
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to 91, with high scores indicating higher function. The
SF-36 measures health-related quality of life by scoring
eight domains (physical function, role limitation due
to physical health, pain, general health perception,
vitality, social function, role limitations due to emotional
health and mental health) from 0 to 100. High scores
indicate good quality of life. The validity of the SF-36 in
patients following a hip fracture is established, as well as
responsiveness to changes in the SF-36 physical function
domain.19 25
Outcomes at 1 year
For long-term follow-up, the primary outcome is a
composite at 1 year after randomisation of all-cause
mortality and non-fatal MI, pulmonary embolism, pneumonia, sepsis and stroke. Individual secondary 1-year
follow-up outcomes include all-cause mortality, vascular
mortality, non-vascular mortality, MI, congestive heart
failure, non-fatal cardiac arrest, coronary revascularisation, stroke, peripheral arterial thrombosis, pulmonary
embolism, deep venous thrombosis, pneumonia, sepsis,
new acute renal failure requiring dialysis, peri-prosthetic
fracture, prosthetic hip dislocation, implant failure, hip
re-operation, new residence in a nursing home, hospital
readmission, persistent postsurgical pain, FIM motor
domain and its mobility and locomotion subscores, and
the SF-36 score.
Adjudication of outcomes
The Event Adjudication Committee is a committee of
clinicians with expertise in perioperative outcomes.
These individuals are blinded to treatment allocation
and adjudicate the following outcomes: myocardial injury
after randomisation, MI, non-fatal cardiac arrest, stroke,
pulmonary embolism, deep vein thrombosis, new congestive heart failure, pneumonia, sepsis and bleeding. All
adjudicators are trained before commencing trial adjudication. We will use the decisions of the outcome adjudicators for all statistical analyses of these events.
Statistical considerations
Sample size
The overall type 1 error rate for the two co-primary
outcomes will be 5% (0.05) and this will be partitioned
between the two co-primary outcomes, taking into account
the overlap between the outcomes (ie, all-cause mortality
is a subset of the composite). Assuming a 20% overlap,
with the pre-specified α of 0.04 for the first co-primary
outcome (all-cause mortality at 90 days), the α of 0.012 for
the second co-primary outcome (composite) was calculated via simulation.
The sample size calculations were performed using a
time-to-event analysis (Cox proportional hazards model
comparison with two equal groups), two-sided α=0.05
using Power Analysis and Sample Size software V.13
(2014) (see table 1).
With a sample size of 3000 patients, the HIP ATTACK
Trial will have 88% power to detect a relative risk
Borges FK, et al. BMJ Open 2019;9:e028537. doi:10.1136/bmjopen-2018-028537

Table 1 Sample size calculations: sample size fixed at
3000 and α for the first co-primary outcome (mortality) fixed
at 0.04 and the second co-primary outcome calculated at
0.012
Power calculation
Control event rate
Sample size fixed at 3000 and α for the first co-primary
outcome (mortality) fixed at 0.04
 HR

12.5%

13.0%

13.5 %

 0.73

0.785

0.801

0.816

 0.70

0.873

0.886

0.897

 0.65

0.96

0.966

0.971

Sample size fixed at 3000 and α for the second co-primary
outcome* at 0.012 (calculated)
 HR

27.5%

30%

32.5%

 0.75

0.916

0.941

0.958

 0.70

0.988

0.993

0.996

 0.65

0.9992

0.9997

0.9999

*Composite outcome of major perioperative complications (ie,
mortality, non-fatal myocardial infarction, pulmonary embolism,
pneumonia, sepsis, stroke, and life-threatening and major
bleeding).

reduction (RRR) of 30% (ie, a HR of 0.70) for the first
co-primary outcome (90-day all-cause mortality) with a
two-sided α=0.04, assuming an event rate of 13.0% in the
control group. Even with an observed RRR of 27% (ie, a
HR of 0.73), the trial would have 80% power for the first
co-primary outcome. The trial will also have 99% power
to detect a 30% RRR (ie, a HR of 0.70) for the second
co-primary outcome assuming a standard care event
rate of 30% with an α=0.012 (two-sided). Even with an
observed RRR of 25% (ie, HR of 0.75), there would be
91% power for the second co-primary outcome assuming
an event rate of 27.5% in the control group.
Main analysis
We will analyse patients in the treatment group to which
they are allocated, according to the intention-to-treat
principle. We will include all patients randomised in
these analyses, regardless of the timing of surgery. We will
compare patients allocated to accelerated medical clearance and surgery with patients allocated to standard care.
We will present the binary analyses using the KaplanMeier estimator. We will use log-rank tests to compare the
rate of occurrence of the primary outcome between the
accelerated care group and the standard care group. We
will use Cox proportional hazards models to estimate the
effect of accelerated care on the HR for the primary and
dichotomous secondary outcomes including the 1-year
outcomes. We will calculate the HRs and their associated 95% CIs. We will estimate the effect of accelerated
care versus standard care on SF-36 and FIM scores with a
generalised linear model. We will infer statistical significance if the computed two-sided p value is <0.05.
5
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Subgroup analysis
Cox proportional hazards model assessing the primary
outcome will provide the basis for evaluating our single
planned subgroup analysis (ie, patients who present to
the hospital ≥4 hours after their hip fracture). We expect
a larger treatment effect in patients who present within
4 hours of their hip fracture. We will infer a subgroup
effect if the interaction term of treatment and subgroup
is statistically significant at p<0.05.
Interim analysis
We will perform two interim efficacy analyses based on the
co-primary outcomes when 50% and 75% of the patients
have been followed for 90 days. The independent Trial
Monitoring Committee (TMC) will employ the modified
Haybittle-Peto rule of 4 SDs (α=0.0001) for analyses in the
first half of the trial (including the first planned interim
analysis) and three SDs (α=0.00047) for all analyses in the
second half. For a finding to be considered significant for
either co-primary outcome, these predefined boundaries
will have to be exceeded in at least two consecutive analyses, three or more months apart. If either co-primary
outcome fulfils these criteria, the TMC will consider initiating discussion with the Project Ooffice Ooperations
Ccommittee about potentially terminating the trial.
The α-level for the final analysis will remain the conventional α=0.05, given the infrequent interim analyses and
associated low α levels, as well as the requirement for
confirmation with subsequent analyses. We will apportion the α between the two co-primary outcomes in the
final analysis. We will split the α with the first co-primary
outcome (all-cause mortality at 90 days) at 0.04 and the
second co-primary outcome (composite) at 0.012, due to
overlap.
At any time during the trial, if safety concerns arise, the
TMC chairperson will assemble a formal meeting of the
full committee. The TMC will make their recommendations to the Project Office Operations Committee after
considering all the available data and any external data
from relevant studies. If a recommendation for termination is being considered the TMC will invite the International Operations Committee to explore all possibilities
before a decision is made.
Trial organisation
PHRI is the coordinating centre for this trial worldwide
and is primarily responsible for the organisation of the
trial, development of the randomisation scheme, the
study database, data consistency checks, data analysis
and coordination of the study centres. The trial structure
includes the following groups: the Project Office Operations Committee, International Operations Committee,
Steering Committee, National Coordinators, Investigators, Coordinating Centre, and Adjudication Committee.
Patient and public involvement
Our approach to patient engagement is guided by the
Canadian Institutes of Health Research strategy for
6

patient-oriented research patient engagement framework
spanning research governance, strategy, and methods.27
Examples include (a) governance auditing—-engaged patient representatives maintain an audit trail of
strategy—and execution—related decisions in order to
guide ongoing activities; (b) ‘Word on the Street’ videos—
brief (40 to 60 s) commentaries target personal experience of our research and are shared via Twitter using Bitly
software and (c) Outcome evaluation—we use an interactive audience response system so patient partners can tell
us, from their perspective, which trial outcomes matter
most. We use this information to inform our future trial
communications strategy.
Ethics and dissemination
We require documentation of Research Ethics Committee
or Institutional Review Board (REC/IRB) approvals
before sites are activated to enrol patients. All committees are described in detail in the Supplement File under
the Supplemental Trial Groups and Investigators section.
Investigators are informed of any protocol amendments,
and REC/IRBs are requested to approve them. Research
personnel or good clinical practice trained healthcare
professionals participating in the study obtain written
informed consent (online supplementary appendix 2)
for each patient before randomisation. All data are stored
on a centrally encrypted, high-security computer system
and kept strictly confidential. The online supplementary
appendix 3, presents the list of the HIP ATTACK trial
participant sites and countries.
Dissemination policy
The knowledge dissemination plan includes traditional
modes of dissemination (ie, publication in a policy-driving
journal, national/international conference presentations) as well as the engagement of influential medical
organisations (ie, emergency medicine and orthopaedic
surgery organisations). Broader dissemination will be
performed by the HIP ATTACK public website (http://
www.
hipattacktrial.
com), Twitter account (@HIPATTACKTrial), Facebook page and LinkedIn Profile. The
Reducing Global Perioperative Risk Multimedia Resource
Centre, linked to Elsevier’s entire online global readership, will disseminate slide and audioinstructional videos,
full-text articles, links to abstracts and data summaries.
Discussion
Hip fractures are a worldwide health concern due to
their high incidence, poor outcomes and high health
economic costs. Population ageing will probably worsen
this scenario in the near future. Age, male gender, clinical comorbidities, dementia, nursing home residency
and surgical delay are associated with an increased risk
of mortality after a hip fracture.28 Surgical timing is the
only potential modifiable risk factor for postoperative
mortality and major complications.
Borges FK, et al. BMJ Open 2019;9:e028537. doi:10.1136/bmjopen-2018-028537
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Evidence from several observational studies, including
systematic reviews and meta-analyses, demonstrates that
early surgery is associated with better outcomes and
with decreased mortality in patients suffering a hip fracture.14 29–31 Uzoigwe and colleagues published prospective data on 2056 patients in UK. Patients who had
surgery more than 12 hours after hip fracture diagnosis
had adjusted OR of 3.8 (95% CI 1.03–14.50; p=0.046)
for in-hospital mortality compared with those who had
surgery within 12 hours.32
Results from an intervention study in Canada demonstrated that coordinated, region-wide efforts directed at
meeting a 48 hours benchmark for hip fracture surgery
was successful in reducing time to surgery, length of
stay, adjusted in-hospital and 1-year mortality.33 There
were 3525 preintervention and 3007 postintervention patients ≥50 years of age. Surgery within 48 hours
increased from 66.8% to 84.6%, length of stay decreased
from 13.5 to 9.7 median days and in-hospital mortality
decreased from 9.6% to 6.8% (all p<0.001). In-hospital
mortality (HR, 0.68; 95% CI 0.57 to 0.81) and mortality
at 1-year follow-up (HR, 0.87; 95% CI 0.79 to 0.96) were
reduced in adjusted analyses.
Hip fracture patients who undergo surgery have worse
outcomes compared with matched patients who undergo
elective hip surgery.34 This suggests that a hip fracture
initiates processes that increase patients’ risk independent of surgery. A hip fracture causes pain, immobilisation
and bleeding, which trigger a cascade of inflammation,
sympathetic activation, hypercoagulability and catabolism
that can ultimately cause acute clinical complications (eg,
thromboembolism, acute MI, infection and death). Delay
in repairing a hip fracture will increase the duration of
time a patient is exposed to these negative physiological
stressors. It is possible that urgent surgical treatment
of a hip fracture will yield benefit, similar to how rapid
treatment of an acute MI and stroke have yielded benefit
from rapid reversal of the underlying physiological
abnormalities.
Although previous hip fracture studies provide insights
into this issue, there are many examples of risk-adjusted
observational studies reporting misleading results. For
example, observational studies suggested harm with
transfusion of older blood; however, subsequent large
RCTs showed older blood was safe.35 Currently, evidence
on best timing to perform hip fracture surgery is based
mostly on observational studies, which are at risk of
residual confounding. These studies may have overestimated the effects of early surgery because sicker patients
likely went to surgery later than less ill patients, due to
clinical optimisation before surgery. On the other hand,
observational data could underestimate the effects
of ultra-early surgery, such as surgery within 6 hours,
which has not been evaluated in clinical studies. Only
large, high-quality RCTs can minimise bias and provide a
valid estimate of treatment effects.
In HIP ATTACK, the goal in the accelerated surgery
arm is to operate on patients as soon as possible, with
Borges FK, et al. BMJ Open 2019;9:e028537. doi:10.1136/bmjopen-2018-028537

a target time of <6 hours, which was demonstrated as
feasible in the HIP ATTACK pilot.15 HIP ATTACK is a
large international trial powered to inform the effect of
accelerated surgery on patient-important outcomes.
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